Ozempic Tracker App
Track Your Semaglutide Protocol
Ozempic (semaglutide 0.25–2 mg weekly) is an FDA-approved GLP-1 receptor agonist for type 2 diabetes that also produces clinically significant weight loss. The SUSTAIN-6 and STEP trials confirmed both glycaemic and cardiometabolic benefits. Shotlee is the free app for logging every weekly injection, tracking your weight trend, and monitoring side effects throughout your dose escalation.
What Is Ozempic (Semaglutide)?
Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist developed by Novo Nordisk and FDA-approved in December 2017 for the treatment of type 2 diabetes in adults. It works by mimicking the incretin hormone GLP-1, stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and activating hypothalamic satiety centres to reduce appetite.
Ozempic is administered as a once-weekly subcutaneous injection starting at 0.25 mg for tolerability, escalating to 0.5 mg, 1 mg, and up to 2 mg as needed. While approved for T2D, Ozempic is widely recognised for producing substantial weight loss — the same molecule at 2.4 mg weekly was approved as Wegovy for obesity. The SUSTAIN-6 cardiovascular outcomes trial demonstrated a 26% reduction in MACE in high-CV-risk T2D patients.
Ozempic Dose Escalation Schedule
Starting dose to build GI tolerance. Not a therapeutic glycaemic dose — this is a tolerability step.
First therapeutic maintenance dose. Adequate glycaemic control achieved here for many patients.
Standard maintenance dose for enhanced HbA1c reduction and weight loss effect.
Maximum approved dose for additional glycaemic and weight benefit. SUSTAIN-10 showed superior HbA1c at 2 mg.
What to Track in Shotlee
Clinical Trial Results (SUSTAIN & STEP Programs)
How to Track Your Ozempic Protocol
Ozempic vs Wegovy: Key Differences
| Feature | Ozempic | Wegovy |
|---|---|---|
| Approved indication | Type 2 diabetes | Obesity / weight managementBest |
| Maximum dose | 2 mg/week | 2.4 mg/week |
| Active ingredient | Semaglutide | Semaglutide |
| Dosing frequency | Once weekly | Once weekly |
| Key trial | SUSTAIN-6 (CV outcomes) | STEP-1 (weight loss) |
| Insurance coverage | T2D indication | Obesity criteria |
Protocol FAQs
Log each weekly injection in Shotlee with the dose (0.25–2 mg), injection site, and any side effects. Shotlee keeps a complete timeline of your protocol history and reminds you when your next weekly dose is due.
Yes. Shotlee supports tracking multiple medications simultaneously, including combination protocols such as Ozempic with metformin, insulin, or other diabetes medications.
Both contain semaglutide. Ozempic (max 2 mg) is approved for type 2 diabetes. Wegovy (max 2.4 mg) is approved for obesity/weight management. Shotlee tracks both medications with full dose support.
Most patients see meaningful weight loss beginning at week 8–12. Maximum effect in the STEP-1 trial occurred around week 68 with 14.9% mean weight loss. Track weekly in Shotlee to see your personal response curve.
Yes. Log your pen lot number, start date, and injection site. Shotlee helps you rotate between abdomen, thigh, and upper arm to prevent lipodystrophy.
Track Your Ozempic Protocol in Shotlee
Free dose logs, weekly weight trends, side effect tracking — all in one place.
📚References & sources
Latest on Semaglutide
Peptides and Health: The Truth Behind the Beauty and Weight Loss Claims
Peptides are the newest buzzword in health and beauty, promising everything from wrinkle reduction to profound weight loss. But does the science actually back up the claims, and are they safe?
7 min read
Svemia Approved: What Canada's New Semaglutide Generic Means for You
Canada's Health Department has cleared Apotex's Svemia, marking a major milestone for generic semaglutide availability and weight loss treatment access.
7 min read
Navigating Medicare's New Path for GLP-1 Weight Loss Coverage
For years, Medicare coverage for GLP-1 medications like Ozempic and Wegovy was strictly limited to diabetes management. A significant shift is underway, however, as a new 'Bridge' program opens doors for weight loss coverage, albeit with specific requirements and nuances that patients must navigate.
6 min read